Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly's shares may appear expensive at first glance, but a closer look reveals a different story. The company's outlook ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the ...

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...

Additionally, Eli Lilly decided to drop CVS Health as its employee drug benefit provider after CVS chose not to cover Lilly’s weight-loss medication. In related news, MeiraGTx saw its stock price ...

Eli Lilly stock has soared in the triple digits over three years. Investors are excited about the company’s portfolio of weight loss drugs, which has generated blockbuster revenue. Investors generally ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...